Birdwatch Note
2023-04-22 03:22:08 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Any claims made on the efficacy of Ivermectin on the symptoms of Covid 19 are improper due to lack of actual clinical data. Protocols for Ivermectin were never included in the treatment options for CV19
Written by F0049203734802940DD41A8E45EC2DEE2DDEC851DF8AB7B6D74EBDF4C82A9331
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1649436237416087552
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1649614536306204676
- noteId - 1649614536306204676
- participantId -
- noteAuthorParticipantId - F0049203734802940DD41A8E45EC2DEE2DDEC851DF8AB7B6D74EBDF4C82A9331 Participant Details
- createdAtMillis - 1682133728469
- tweetId - 1649436237416087552
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 1
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Any claims made on the efficacy of Ivermectin on the symptoms of Covid 19 are improper due to lack of actual clinical data. Protocols for Ivermectin were never included in the treatment options for CV19
Note Ratings
rated at | rated by | |
2023-04-22 10:01:01 -0500 | Rating Details | |
2023-04-21 22:41:48 -0500 | Rating Details | |
2023-04-22 09:46:35 -0500 | Rating Details | |
2023-04-22 10:34:01 -0500 | Rating Details | |
2023-04-21 23:17:09 -0500 | Rating Details | |
2023-04-22 11:18:17 -0500 | Rating Details | |
2023-04-22 00:29:52 -0500 | Rating Details | |
2023-04-21 22:34:30 -0500 | Rating Details | |
2023-04-22 01:04:45 -0500 | Rating Details | |
2023-04-22 01:40:57 -0500 | Rating Details | |
2023-04-22 09:27:24 -0500 | Rating Details | |
2023-04-22 02:38:01 -0500 | Rating Details | |
2023-04-22 08:59:23 -0500 | Rating Details | |
2023-04-22 01:46:54 -0500 | Rating Details | |
2023-04-22 06:39:59 -0500 | Rating Details | |
2023-04-22 18:00:06 -0500 | Rating Details | |
2023-04-23 13:39:26 -0500 | Rating Details | |
2023-04-22 23:32:12 -0500 | Rating Details | |
2023-04-22 06:33:44 -0500 | Rating Details | |
2023-04-21 22:27:16 -0500 | Rating Details | |
2023-04-22 02:47:37 -0500 | Rating Details | |
2023-04-21 22:26:11 -0500 | Rating Details | |
2023-04-22 08:41:34 -0500 | Rating Details | |
2023-04-22 09:47:30 -0500 | Rating Details | |
2023-04-22 08:03:56 -0500 | Rating Details | |
2023-04-22 20:58:33 -0500 | Rating Details | |
2023-04-22 00:28:51 -0500 | Rating Details | |
2023-04-24 02:24:27 -0500 | Rating Details | |
2023-04-22 06:01:34 -0500 | Rating Details | |
2023-04-23 21:38:43 -0500 | Rating Details | |
2023-04-22 00:20:01 -0500 | Rating Details | |
2023-04-22 07:16:10 -0500 | Rating Details | |
2023-04-22 09:41:36 -0500 | Rating Details | |
2023-04-22 10:01:01 -0500 | Rating Details | |
2023-04-21 22:41:48 -0500 | Rating Details | |
2023-04-22 09:46:35 -0500 | Rating Details | |
2023-04-22 10:34:01 -0500 | Rating Details | |
2023-04-21 23:17:09 -0500 | Rating Details | |
2023-04-22 11:18:17 -0500 | Rating Details | |
2023-04-22 00:29:52 -0500 | Rating Details | |
2023-04-21 22:34:30 -0500 | Rating Details | |
2023-04-22 01:04:45 -0500 | Rating Details | |
2023-04-22 01:40:57 -0500 | Rating Details | |
2023-04-22 09:27:24 -0500 | Rating Details | |
2023-04-22 02:38:01 -0500 | Rating Details | |
2023-04-22 08:59:23 -0500 | Rating Details | |
2023-04-22 01:46:54 -0500 | Rating Details | |
2023-04-22 06:39:59 -0500 | Rating Details | |
2023-04-22 18:00:06 -0500 | Rating Details | |
2023-04-23 13:39:26 -0500 | Rating Details | |
2023-04-22 23:32:12 -0500 | Rating Details | |
2023-04-22 06:33:44 -0500 | Rating Details | |
2023-04-21 22:27:16 -0500 | Rating Details | |
2023-04-22 02:47:37 -0500 | Rating Details | |
2023-04-21 22:26:11 -0500 | Rating Details | |
2023-04-22 08:41:34 -0500 | Rating Details | |
2023-04-22 09:47:30 -0500 | Rating Details | |
2023-04-22 08:03:56 -0500 | Rating Details | |
2023-04-22 20:58:33 -0500 | Rating Details | |
2023-04-22 00:28:51 -0500 | Rating Details | |
2023-04-24 02:24:27 -0500 | Rating Details | |
2023-04-22 06:01:34 -0500 | Rating Details | |
2023-04-23 21:38:43 -0500 | Rating Details | |
2023-04-22 00:20:01 -0500 | Rating Details | |
2023-04-22 07:16:10 -0500 | Rating Details | |
2023-04-22 09:41:36 -0500 | Rating Details | |
2024-03-30 09:26:56 -0500 | Rating Details |